A moving target: Inactivating btk mutations as drivers of follicular lymphoma

Jumana Afaghani, Justin Taylor

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Drugs that target Bruton tyrosine kinase (BTK) have been highly successful and changed the landscape of therapies in B-cell lymphomas. However, their lower rates of effectiveness in follicular lymphoma are unexplained. Recent work describes inactivating BTK mutations that show that at least some follicular lymphomas do not require BTK.

Original languageEnglish (US)
Pages (from-to)2123-2125
Number of pages3
JournalClinical Cancer Research
Volume27
Issue number8
DOIs
StatePublished - Apr 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A moving target: Inactivating btk mutations as drivers of follicular lymphoma'. Together they form a unique fingerprint.

Cite this